Carregant...
Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes
Inhibitors of sodium-glucose co-transporter type 2 (SGLT2), such as canagliflozin and dapagliflozin, are recently approved for treatment of type 2 diabetes. These agents lower blood glucose mainly by increasing urinary glucose excretion. Compared with placebo, SGLT2 inhibitors reduce hemoglobin A1c...
Guardat en:
| Publicat a: | World J Diabetes |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4265871/ https://ncbi.nlm.nih.gov/pubmed/25512787 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v5.i6.854 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|